6.162

1.12% -0.068

Achieve Life Sciences Inc (ACHV)

Overview News Price History Option Chain Financials Why ACHV Down? Discussions Forecast Stock Split

Achieve Life Sciences Inc stock is traded at $6.162, with a volume of 568.38K. It is down -1.12% in the last 24 hours and up +17.56% over the past month. Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.

Previous Close:

$6.23

Open:

$6.23

24h Volume:

568.38K

Relative Volume:

0.32

Market Cap:

$632.38M

Revenue:

Net Income/Loss:

$-54.65M

P/E Ratio:

-4.759

EPS:

-1.2948

Net Cash Flow:

$-49.47M

1W Performance:

+22.95%

1M Performance:

+17.56%

6M Performance:

+31.06%

1Y Performance:

+172.57%

1-Day Range:

$6.0901

$6.34

1-Week Range:

$4.91

$6.34

52-Week Range:

$2.015

$6.34

Achieve Life Sciences Inc Stock (ACHV) Company Profile

Name

Achieve Life Sciences Inc

Sector

Healthcare (1097)

Industry

Biotechnology (616)

Phone

425-686-1500

Address

22722 29TH DR. SE, SEATTLE, BC

Employee

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

ACHV's Discussions on Twitter

Compare ACHV vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ACHV Achieve Life Sciences Inc	6.16	618.01M	0	-54.65M	-49.47M	-1.2948
VRTX Vertex Pharmaceuticals Inc	497.67	124.70B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	629.46	66.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	925.27	55.17B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	188.32	38.71B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	298.51	38.90B	4.29B	577.22M	641.34M	4.2086

Achieve Life Sciences Inc Stock (ACHV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-21-26	Initiated	Canaccord Genuity	Buy
Nov-25-25	Initiated	Citizens JMP	Mkt Outperform
Aug-21-25	Initiated	H.C. Wainwright	Buy
Nov-14-24	Initiated	Rodman & Renshaw	Buy
Sep-27-24	Initiated	Raymond James	Strong Buy
May-10-23	Reiterated	Maxim Group	Buy
Jun-23-21	Initiated	Oppenheimer	Outperform

View All

Achieve Life Sciences Inc Stock (ACHV) Latest News

Jun 29, 2026

Achieve Life Sciences, Inc.(NasdaqCM:ACHV) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com

Jun 29, 2026

Achieve Life Sciences, Inc.(NasdaqCM: ACHV) added to Russell 2000 Index - marketscreener.com

Jun 29, 2026

Achieve Life Sciences (ACHV) Joins Russell 2000 Index - GuruFocus

Jun 29, 2026

Achieve Life Sciences added to Russell 2000 index - Investing.com

Jun 29, 2026

Achieve Life Sciences added to Russell 2000 index By Investing.com - Investing.com South Africa

Jun 29, 2026

Achieve Life Sciences Joins Russell 2000® Index - GlobeNewswire

Jun 29, 2026

Achieve Life Sciences, Inc.(NasdaqCM: ACHV) added to Russell 2000 Growth Benchmark - marketscreener.com

Jun 29, 2026

Achieve Life Sciences, Inc.(NasdaqCM: ACHV) added to Russell 3000E Index - marketscreener.com

Jun 29, 2026

Achieve Life Sciences, Inc.(NasdaqCM: ACHV) added to Russell 3000E Growth Benchmark - marketscreener.com

Jun 29, 2026

Jun 28, 2026

Enterprise value to revenue forward of Achieve Life Sciences, Inc. – NASDAQ:ACHV - TradingView

Jun 28, 2026

Price to earnings forward of Achieve Life Sciences, Inc. – NASDAQ:ACHV - TradingView

Jun 28, 2026

Price to sales forward of Achieve Life Sciences, Inc. – NASDAQ:ACHV - TradingView

Jun 28, 2026

Enterprise value to EBITDA forward of Achieve Life Sciences, Inc. – NASDAQ:ACHV - TradingView

Jun 28, 2026

Jun 26, 2026

Achieve Life Sciences (ACHV) Receives Strong Buy Rating with $20 Target - GuruFocus

Jun 26, 2026

Raymond James resumes Achieve Life Sciences stock coverage with Strong Buy - Investing.com Canada

Jun 26, 2026